Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
WWAKAMOTO PHARMACEUTICAL CO.,LTD. logo
4512TSE Standard

WAKAMOTO PHARMACEUTICAL CO.,LTD.

わかもと製薬 Yahoo Finance

Recent & upcoming events

Aug 5
Earnings 2:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
Jun 21
Shareholder meeting Time TBD
Shareholders' meeting
Venue: <UNKNOWN> Details
Add to Google Calendar
May 15
Earnings 2:00
FY earnings announcement (scheduled)
Add to Google Calendar
Sep 27
Est.
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Sep 28
Est.
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Oct 28
Est.
Earnings 2:00 approx.
Q2 earnings
Add to Google Calendar
2027
Jan 13
Est.
Earnings 1:00 approx.
Q3 earnings
Add to Google Calendar
Mar 28
Est.
Dividend Time TBD
Last day with rights (year-end)
Add to Google Calendar
Mar 29
Est.
Ex-dividend Time TBD
Ex-rights date (year-end)
Add to Google Calendar
Apr 7
Est.
Earnings 2:00 approx.
Full-year earnings
Add to Google Calendar
Jun 30
Est.
Earnings 2:00 approx.
Full-year earnings
Add to Google Calendar

KPI highlights

FY26
Revenue ¥9.91B YoY +27.2%
Operating income ¥256M margin 2.6%
Net income ¥227M YoY +252.6%
EPS —
P/E —
ROE —

Company guidance

FY2027/03 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥11.00B +11.0%
Operating income ¥200M -21.7%
Net income ¥230M +1.2%
EPS ¥7 —

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q1FY23 Q2FY23 Q3FY23 Q4FY24 Q1FY25 Q2
Revenue ¥2.39B¥1.86B¥1.76B¥1.97B¥2.15B—
Operating income ¥108M¥-58M¥-270M¥69M¥64M—
Net income ¥28M¥101M¥-324M¥17M¥314M—
Operating CF ——————

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2021–2026）

事業法人 33%国内機関 11.4%アクティビスト 8.6%個人 5.8%未開示 41.2%202120222023202420252026
事業法人国内機関アクティビスト個人未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

ロート製薬株式会社 11.4%ロート製薬株式会社キッセイ薬品工業株式会社 10.9%キッセイ薬品工業株式会社AVI JAPAN OPPORTUN 8.6%AVI JAPAN OPPORTUNITY TRUST PLC（常任代理人　株式会社みずほ銀行 決済営業部）株式会社ブレストシーブ 7.2%株式会社ブレストシーブわかもと製薬取引先持株会 5.8%わかもと製薬取引先持株会朝日生命保険相互会社 3.5%朝日生命保険相互会社日本ゼトック株式会社 3.5%日本ゼトック株式会社株式会社みずほ銀行 3.2%株式会社みずほ銀行SG／UCITS V／INV（常任代 2.5%SG／UCITS V／INV（常任代理人　香港上海銀行東京支店　セキュリティーズ・サービシズ・オペレーションズアクサ生命保険株式会社 2.3%アクサ生命保険株式会社202120222023202420252026

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
ロート製薬株式会社 3,971,000 11.4% Yuho (EDINET)
キッセイ薬品工業株式会社 3,778,000 10.9% Yuho (EDINET)
AVI JAPAN OPPORTUNITY TRUST PLC 2,998,000 8.6% Yuho (EDINET)
株式会社ブレストシーブ 2,500,000 7.2% Yuho (EDINET)
わかもと製薬取引先持株会 2,012,000 5.8% Yuho (EDINET)
朝日生命保険相互会社 1,204,000 3.5% Yuho (EDINET)
日本ゼトック株式会社 1,201,000 3.5% Yuho (EDINET)
株式会社みずほ銀行 1,093,000 3.2% Yuho (EDINET)
SG／UCITS V／INV 867,000 2.5% Yuho (EDINET)
アクサ生命保険株式会社 789,000 2.3% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

4/9 4 of 9 items lack data

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 1.4%
— Positive operating cash flow No data
✓ ROA improved YoY 0.4% → 1.4%
— Operating CF exceeds net income (accrual quality) No data
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 77.4% → 72.8%
— Current ratio improved No data
✓ No dilution (shares outstanding did not increase) 34,838,000 → 34,838,000
— Gross margin improved No data
✓ Asset turnover improved 0.52× → 0.60×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY26
Equity ratio —
Current ratio —
Years of positive operating CF 3 of last 6 yrs
Payout ratio 53%
Latest fiscal year result Profit (net income ¥227M)

Performance history

Last 10 years
0億円27億円55億円82億円109億円 FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Income & assets

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Revenue 10810910710989.083.886.677.477.999.1
Operating income 0.87-0.73-3.91-9.96-7.55-0.131.41-1.96-4.582.56
Ordinary income 1.03-0.80-4.09-9.11-6.050.722.43-1.62-4.092.56
Net income 0.951.26-1.81-16.6-6.022.391.381.090.642.27
Total assets 179180178160146150157154150165
Equity 139141138119114115119120116120

Indicators & cash flow

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
EPS ———¥-48¥-17¥7¥4¥3¥2—
ROE ——————————
Operating CF ———-6.152.04-2.981.991.73-7.49—
Investing CF ———-1.10-0.761.531.432.620.33—
Financing CF ———-0.41-0.01-0.01-0.01-1.04-1.03—
FCF ———-3.62-3.19-0.014.21-7.02-10.9—

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data